Clinical Scorecard: Efficacy and Safety of Omalizumab in Chinese Pediatric Patients Under 12 with Chronic Urticaria: A Case Series Analysis
At a Glance
Category
Detail
Condition
Chronic urticaria (CU), including chronic spontaneous urticaria (CSU)
Key Mechanisms
Omalizumab is an anti-IgE antibody that targets IgE-mediated pathways involved in urticaria
Target Population
Chinese pediatric patients under 12 years with refractory chronic urticaria
Care Setting
Pediatric Allergy and Immunology Clinic, outpatient clinical setting
Key Highlights
All 13 pediatric patients showed rapid clinical improvement within one week after initial omalizumab dose.
Significant reduction in median Urticaria Activity Score over 7 days (UAS7) from 20.0 to 4.0 at week 4 (p=0.001).
No adverse events reported across 74 administered doses, indicating excellent safety and tolerability.
Guideline-Based Recommendations
Diagnosis
Chronic urticaria diagnosis based on presence of wheals and/or angioedema for more than 6 weeks.
Use Urticaria Activity Score over 7 days (UAS7) to assess disease activity.
Management
First-line treatment: second-generation H1-antihistamines at licensed or high doses.
Second-line treatment: omalizumab recommended for patients aged ≥12 years with inadequate response to antihistamines; this study supports use in children under 12 with refractory CU.
Omalizumab administered as 150 mg subcutaneous injection.
Monitoring & Follow-up
Monitor UAS7 scores to evaluate treatment response; well-controlled disease defined as UAS7 ≤6 at week 4.
Monitor for adverse events during and after omalizumab administration.
Risks
No adverse events reported in this study; however, patients with autoimmune disorders or on immunosuppressants were excluded.
Potential residual mild disease activity in patients with high baseline UAS7 and comorbid allergic rhinitis.
Patient & Prescribing Data
13 Chinese children under 12 years with refractory chronic urticaria unresponsive to high-dose antihistamines
Rapid symptom control achieved within one week; oral antihistamines discontinued within 4 weeks; 84.6% achieved well-controlled disease by week 4; excellent safety profile with no adverse events reported.
Clinical Best Practices
Consider omalizumab as a second-line therapy for children under 12 with refractory chronic urticaria after failure of high-dose antihistamines.
Use UAS7 scoring to objectively assess disease severity and treatment response.
Obtain informed consent from legal guardians prior to omalizumab administration.
Exclude patients with autoimmune disorders or on immunosuppressive therapies when considering omalizumab.
Monitor patients closely for clinical improvement and adverse events during treatment.
